Lapatinib in combination with capecitabine in the management of ErbB2-positive (HER2-positive) advanced breast cancer.
Lapatinib is an oral, reversible, dual inhibitor of epidermal growth factor receptor ErbB1 (EGFR) and human epidermal growth factor receptor type 2 ErbB2 (HER2). Results of a phase III study comparing lapatinib plus capecitabine with capecitabine alone in women with ErbB2-overexpressing advanced breast cancer previously treated with an anthracycline, a taxane, and trastuzumab were reported early based on superiority of the combination in prolonging time to tumor progression (TTP). An updated analysis in 399 women supports the earlier findings. In this updated analysis, TTP (hazard ratio [HR] 0.57) favored lapatinib plus capecitabine. Survival trended in favor of the combination. The incidence of cardiac events was numerically higher in the combination arm (5 cases in the combination arm, 2 cases in the monotherapy arm).
Kaufman
Bella
B
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Stein
Steven
S
Casey
Michelle A
MA
Newstat
Beth O
BO
Cancer Res. 2006 Feb 1;66(3):1630-9
16452222
Science. 1987 Jan 9;235(4785):177-82
3798106
Ann Oncol. 2007 Apr;18 Suppl 2:ii9-11
17491064
Oncologist. 2006 Apr;11(4):318-24
16614227
J Clin Oncol. 2005 Apr 20;23(12):2866-8; discussion 2868-9
15838006
J Clin Oncol. 2002 Mar 1;20(5):1215-21
11870163
N Engl J Med. 2006 Dec 28;355(26):2733-43
17192538
J Clin Oncol. 2000 Feb;18(3):591-9
10653874
Mol Cancer Ther. 2001 Dec;1(2):85-94
12467226
Br J Cancer. 2004 Aug 16;91(4):639-43
15266327